Stronger than Ozempic. Not exactly legal. ‘Reta’ has entered the chat.
An experimental, unlicensed weight-loss drug known as 'Reta' is sparking health alarms and hospitalizations as it surfaces in unregulated markets.
📍 Where it landed
An experimental and unlicensed weight-loss drug called 'Reta' was sold at a Brooklyn bodega. The drug was linked to liver damage, users turning yellow, and a wave of hospitalisations.
Epilogue added 88d ago, after coverage quieted.
Questions people are asking
What is 'Reta'?
Reta is an experimental, unlicensed weight-loss drug and peptide that is described as being stronger than Ozempic.
Where is the drug being sold?
According to AOL.com and CBS News, the drug has been sold at a Brooklyn bodega.
What are the reported side effects?
Coverage from The Sun and AFR links the drug to liver damage, users turning yellow, and a wave of hospitalizations.
What happened
- Velocity & Diffusion: Coverage escalated across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: An experimental, unlicensed weight-loss drug known as 'Reta' is sparking health alarms and hospitalizations as it surfaces in unregulated markets.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
An unapproved weight-loss drug called 'Reta' is being sold through unofficial channels, including a Brooklyn bodega. Described as an experimental peptide and stronger than Ozempic, the drug is being marketed as a weight-loss quick fix.
Coverage from The Sun and AFR highlights severe health risks, linking the substance to liver damage and a wave of hospitalizations. The Sun reports that users of the unlicensed drug have turned yellow.
Other reports from CBS News and AOL.com focus on the availability of the drug in retail settings. Future developments depend on the scale of hospitalizations and the legal status of the drug's distribution, as current coverage emphasizes its unlicensed and experimental nature.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 91d ago.
The reporting (5)
-
-
-
-
-
Stronger than Ozempic. Not exactly legal. ‘Reta’ has entered the chat. The Washington Post · 92d ago broke it first
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
Rabies cases increased 17 percent in July and August, CDC says
Public health officials report a notable spike in human rabies exposures across the United States during the summer months.
Nicotine vapes best chance to quit smoking, major review finds
A new major review crowns nicotine vapes the most effective tool for quitting smoking, sparking health‑policy debate.
Scientists stunned by children's lung recovery in ultra low emission zone
New studies reveal a dramatic recovery in children's lung health following the implementation of London's ultra low emission zone.
Finish the fight against HIV/AIDS
4 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Doctors warn of very serious Vibrio infection spreading in Chesapeake Bay
Doctors warn of rising Vibrio infections in Chesapeake Bay
The Hidden Impact Of Trump's Public Health Cuts Is Starting To Appear
5 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.